Abingdon, United Kingdom

Summit Corporation

summitplc.com
Abingdon, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.


Patent
Summit Corporation | Date: 2013-02-07

A specialized box with integrated dividers is suitable for transporting multiple rectangular products, such as set top boxes. The box is formed of a single sheet of material, scored in six panels so that a leading panel forms a partition around which the other panels are folded and secured, with the final panel partially overlapping the second panel to form a joined side of the box. An insert with two walls, formed of a single sheet of material, can be folded into a rectangular shape and inserted in the box to create walls between the partition and each parallel side of the box. Cushioning pads can be attached to bottom flaps of the box. When flat, multiple boxes can be compactly stored or transported on a pallet. When folded into a cube, the box holds up to four rectangular products in four separate, protected compartments within the box.


Patent
Summit Corporation | Date: 2015-12-18

Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.


Patent
Summit Corporation | Date: 2015-08-19

Disclosed are pharmaceutical compositions comprising the compound 2,2-di(pyridin-4-yl)-1H,1H-5,5-bibenzo[d]imidazole, or a pharmaceutically acceptable N-oxide, salt, hydrate or solvate thereof, and a pharmaceutically acceptable excipient. The compositions find application in methods of treating infection with Clostridium difficile and in methods of treating Clostridium difficile-associated disease (CDAD).


This invention relates to pharmaceutical compositions comprising 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (C1100), to processes for preparing the compositions, and to various therapeutic uses of the combinations. Also provided is a method of treatment of Duchenne muscular dystrophy or Becker muscular dystrophy using the compositions.


Patent
Summit Corporation | Date: 2014-02-24

A lift assembly is provided. In one embodiment, the lift assembly may be used to raise and lower a bed, such as in a recreational vehicle. The lift may include a platform assembly which is movable between upper and lower positions. The lower position may be located in a lower horizontal plane than the upper position. The lift assembly may further include at least one movable member connected to the platform assembly and which may be activated to perform functions selected from the group consisting of raising the platform assembly, lowering the platform assembly, and combinations thereof. The lift assembly may also include means for positioning the platform assembly in the lower horizontal plane. In some embodiments, the means may be a cradle, while in other embodiments, the means may be a latch. The assembly may include a plurality of movable members which are activated by an electric motor.


Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt, derivative, solvate, isomer, tautomer, N-oxide, ester, prodrug, isotope or protected form thereof, which are of use as OGA inhibitors, for example in the treatment of various conditions and diseases, including neurodegenerative disorders.


Patent
Summit Corporation | Date: 2015-02-06

Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.


Patent
Summit Corporation | Date: 2016-11-23

Disclosed are pharmaceutical compositions comprising the compound 2,2-di(pyridin-4-yl)-1H,1H-5,5-bibenzo[d]imidazole, or a pharmaceutically acceptable N-oxide, salt, hydrate or solvate thereof, and a pharmaceutically acceptable excipient. The compositions find application in methods of treating infection with Clostridium difficile and in methods of treating Clostridium difficile-associated disease (CDAD).


Patent
Summit Corporation | Date: 2013-07-11

There are disclosed compound of Formula (1): A_(1), A_(2), A_(3 )and A_(4 )which may be the same or different, represent N or CR_(1), X is a divalent group selected from O, S(O)_(n), CW, NR_(4), NC(O)R_(5 )and CR_(6)R_(7), W is O, S, NR_(20), Y is N or CR_(8), one of R_(4), R_(5), R_(6), R_(8), R_(9 )and NR_(20 )represents -L-R_(3), in which L is a single bond or a linker group, additionally, R_(1), R_(3)-R_(9), which may be the same or different, independently represent hydrogen or a substituent and R_(20 )represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO_(2), NR_(30)R_(31), in which R_(30 )and R_(31), which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R_(30 )and R_(31 )may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A_(1)-A_(4 )each represent CR_(1), then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR_(6)R_(7), R_(6 )and R_(7), together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

Loading Summit Corporation collaborators
Loading Summit Corporation collaborators